Clinical effectiveness of eprosartan and hydroxyzine in patients with mild to moderate arterial hypertension and coexisting anxiety

Abstract

Aim. То evaluate clinical effectiveness of eprosartan and hydroxyzine in patients with mild to moderate arterial hypertension (AH) and coexisting anxiety.

Material and methods. The study included 34 patients (8 men, 26 women) aged 36—76 years (mean age 56,7+11,1 years) with Stage I-II AH. Stage I AH was registered in 6 participants, Stage II AH — in 28; mean AH duration was 9,29+6,2 years. All patients were randomised into two groups: main group (MG) and control group (CG). Fro 4 weeks, all participants received eprosartan (600 mg/day); MG individuals also received hydroxyzine (25—50 mg/day). The dynamics of clinico-psychological status and cognitive function in AH patients was assessed.

Results. Hydroxyzine therapy was associated with improved psychological status: mean score for anxiety subscale reduced by 42'% (-5,2+0,47 points; p<0,0001), for depression subscale — by 19 % (-1,62+0,61 points; p<0,0001); for stress level — by 28 % (from 5,7+0,40 to 4,1+0,43 points; p<0,001). No significant changes in cognitive dysfunction severity, according to Munsterberg test results, were observed. In both groups, systolic and diastolic blood pressure (SBP, DBP) levels reduced: SBP — by 23,8+2,77 and 22,8+2,60 mm Hg in MG and CG, respectively; DBP — by 13,4+1,69 and 14,8+2,02 mm Hg, respectively.

Conclusion. Hydroxyzine therapy in a fixed dose of 25 mg twice per day was effective in treating mild to moderate anxiety disorders among patients with mild to moderate AH.